Is ENTYVIO better than Humira?

0 votes
asked Feb 19, 2022 in Other- Health by Freedome (1,210 points)
Is ENTYVIO better than Humira?

1 Answer

0 votes
answered Feb 20, 2022 by Ragbone (3,810 points)
ENTYVIO is better than Humira and Entyvio conferred superior clinical remission and mucosal healing compared with Humira among people with moderately to severely active ulcerative colitis.

Most often the Entyvio side effects are mild and do go away within a few weeks to a few months of taking Entyvio.

The drug Entyvio which is also known as Vedolizumab belongs to a class of drugs known as monoclonal antibodies.

ENTYVIO can cause shortness of breath but if the shortness of breath last longer than 30 minutes or so you should see a doctor or get medical help if you're having trouble breathing.

An Entyvio Infusion takes around 30 minutes each.

Long-term use of Entyvio was shown to be safe and effective in patients with moderate-to-severe ulcerative colitis and Crohn's disease through 5 years, according to interim results from the ongoing GEMINI open-label long-term safety study presented at the 12th Congress of the European Crohn's and Colitis Organization.

Entyvio does need to be refrigerated so that it does not go bad.

ENTYVIO is an immunosuppressant and is the first and only gut-selective biologic therapy with no known systemic immunosuppressive effects and the only biologic treatment approved for use in UC patients who have had an inadequate response, loss of response or were intolerant to infliximab, a TNFα antagonist.

ENTYVIO is safe when administered in the proper dosages and taken as directed.

The success rate of Entyvio is 98%

Entyvio is 98% successful although not everyone sees results from it.

Entyvio can cause mood swings as it's a common side effect of Entyvio.

The ommon side effects of taking Entyvio include mood swings, moon face, and weight gain.

Entyvio does not cause hair loss.

And you shouldn't have hair loss or weight gain from Entyvio.

You can drink alcohol while on Entyvio as alcohol does not interact with Entyvio although just be aware that the alcohol can worsen some of the side effects of taking Entyvio such as nausea and headaches.

When Entyvio is working the symptoms of your condition should start going away or getting better.

Some people who take Entyvio will see results in as little as 6 weeks, though it may take up to 14 weeks to have any effect.

However, some people do not respond at all to Entyvio.

Some people stay on Entyvio for 14 weeks and some stay on Entyvio for a year or even longer.

If after 14 weeks of being on Entyvio, you do not have a therapeutic benefit with Entyvio your doctor may discontinue your Entyvio treatment.

Entyvio is usually given and administered every 8 weeks which is about 6 doses per year.

Entyvio does not have a black box warning as it's selective in it's targeting, even though it is administered intravenously.

After an Entyvio Infusion you may sometimes drive as long as you're not dizzy.

It's best to wait awhile after taking Entyvio to see how you feel before you drive as some people have reported feeling dizzy after taking Entyvio and some people don't get dizzy or the dizziness goes away after awhile.

The Entyvio medication is pretty expensive and costs around $6,700.00 for a supply of one 300 mg vial of powder for injection.

Entyvio is an injection and is given as an injection just under the skin.

High Blood Pressure is a side effect of ENTYVIO for some people.

Entyvio can be administered at home.

Entyvio was approved as a self-injectable subcutaneous format for at-home maintenance treatment of adult patients 18 years or older with moderately to severely active ulcerative colitis.

The medicine ENTYVIO is owned by and made by Millennium Pharmaceuticals, Inc.

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.

Entyvio was launched in both the U.S. and E.U. market in June 2014 and has been on the market for over 7 years in those countries.

Entyvio, from Takeda Pharmaceuticals, was first approved by the U.S. Food and Drug Administration (FDA) on May 20, 2014.

ENTYVIO (vedolizumab), an integrin receptor antagonist, is a humanized IgG1 monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin.

ENTYVIO has an approximate molecular weight of 147 kilodaltons.

The FDA approved ENTYVIO based on evidence from two clinical trials in patients with moderate to severe ulcerative colitis.

The trials were conducted in 34 countries around the world.

Entyvio isn't a systemic immunosuppressant. (Systemic drugs affect your whole body.)

Entyvio has a selective effect on your gut. It doesn't affect your entire immune system.

Entyvio contains the drug vedolizumab. Vedolizumab isn't available as a generic drug.

It's only available as Entyvio.

98,443 questions

94,727 answers

1,269 comments

6,992,496 users

...